Device Trial Radar · NCT03810573
Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Mar 1, 2024
Primary completion
Dec 31, 2026
Study completion Dec 1, 2028
Sponsor
- Lead sponsor
- Bone Biologics CorpNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 18, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 17 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this clinical study is to evaluate the safety and effectiveness of NB1 Bone Graft in subjects with degenerative disc disease undergoing transforaminal lumbar interbody fusion. It is estimated that up to 30 participants will be enrolled in approximately 3 clinical sites. During baseline and follow-up assessments, patients will be asked to undergo x-rays and CT scans; adverse events and immunology will be collected, and; participants will be requested to complete participant questionnaires regarding quality of life, pain and function.
Conditions
- Degenerative Disc Disease
- Spondylolisthesis
Interventions
NB1Device
rhNELL-1/DBX
Primary outcomes
What the sponsor says the trial is designed to measure.
- FusionTime frame: 12 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
St Vincent Melbourne
Fitzroy, Australia · Recruiting
Monash Medical Center
Clayton, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.